Terremoto Biosciences
Terremoto Biosciences, founded in 2021 and based in South San Francisco, California, is a biotechnology company specializing in covalent drug discovery and development. The company leverages lysine-based covalency to create highly targeted, small molecule medicines with unmatched selectivity and potency. Terremoto Biosciences has secured significant funding, including a $75 million Series A round in 2022 and a $175 million Series B round in 2023, to advance its innovative drug development programs. The company was co-founded by Peter Thompson, Matthew Jacobson, and Jack Taunton, and recently appointed Charles Baum as CEO.Recent Posts by Terremoto Biosciences
- Join Terremoto's Talent NetworkSAN FRANCISCO, CAPosted 15 days ago•Similar jobs
- Director/Sr. Director, Analytical DevelopmentSAN FRANCISCO, CAPosted 30+ days ago•Similar jobs
- Director/Sr. Director, Analytical Development/Quality ControlSAN FRANCISCO, CAPosted 30+ days ago•Similar jobs
- Sr. Executive AssistantSAN FRANCISCO, CAPosted 30+ days ago•Similar jobs
1-4 of 4